TransCode Advances Colorectal Cancer Drug to Phase 2
TransCode Therapeutics, a public biotech company, announced its lead drug TTXMC138 for colorectal cancer has advanced to Phase 2 trials. The drug targets microRNA-10b, a key regulator in metastatic cancer. Phase 1 results showed safety and some efficacy, with 71% of patients experiencing stable disease. The company has raised $100M with no long-term debt. Phase 2 trials focus on colorectal cancer, a high-mortality disease with unmet medical needs.


